A. Liaskas
YOU?
Author Swipe
View article: 346 | RITUXIMAB‐DOSE‐ADJUSTED EPOCH VERSUS RITUXIMAB‐CHOP IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA
346 | RITUXIMAB‐DOSE‐ADJUSTED EPOCH VERSUS RITUXIMAB‐CHOP IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA Open
View article: P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP
P1178: THE APPLICABILITY OF PROGNOSTIC MODELS UNDER RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): A COMPARISON WITH R-CHOP Open
Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: The rarity of PMLBCL has prevented the development of dedicated, powerful and validated prognostic systems. The International Prognostic Index (IPI) and its age-adjusted var…
View article: TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY
TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME OF PATIENTS WITH HODGKIN LYMPHOMA EXPERIENCING VERY LATE RELAPSES AFTER CHEMOTHERAPY ± RADIOTHERAPY Open
Background: Despite the excellent long-term outcome of patients with Hodgkin Lymphoma (HL), some cases will be primary refractory or will eventually relapse, mainly within the first 2 years from diagnosis. Patients with sustained complete …
View article: P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS
P1230: PET/CT IMAGING FOR RESPONSE ASSESSMENT AND TREATMENT GUIDANCE AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH(R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL):THE GREEK EXPERIENCE ON 107 PATIENTS Open
Background: The prognostic significance of end-of-treatment PET/CT (EOT-PET) has been already evaluated in PMLBCL under R-CHOP or R-MACOP-B. Patients with clearly positive scans have inferior outcomes even after consolidative radiotherapy …
View article: P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES
P1229: RITUXIMAB-DOSE-ADJUSTED EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): REAL-LIFE EXPERIENCE ON 225 PATIENTS FROM 4 COUNTRIES Open
Background: Real-life studies of moderate size have shown satisfactory but less impressive results compared with the initial study of R-da-EPOCH in PMLBCL. However, the strategies regarding the use of consolidative radiotherapy (RT) and th…
View article: PF297 COMPARISON OF RITUXIMAB DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) WITH RITUXIMAB‐CHOP (R‐CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL)
PF297 COMPARISON OF RITUXIMAB DOSE‐ADJUSTED EPOCH (R‐DA‐EPOCH) WITH RITUXIMAB‐CHOP (R‐CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL) Open
Background: R‐da‐EPOCH provided excellent results in PMLBCL in a phase 2 NCI trial and appeared to obviate the need for consolidative radiotherapy (RT). However, there is no direct randomized comparison of R‐da‐EPOCH vs R‐CHOP. A recent re…
View article: PF472 VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME
PF472 VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME Open
Background: Risk‐adapted treatment strategies have improved the long‐term outcome of patients with Hodgkin Lymphoma (HL) and traditionally the disease is considered cured after a 5‐year continuous first complete remission (CR1). However, o…